Ionis Pharmaceuticals (IONS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ionis Pharmaceuticals, Inc. announced successful topline results from the Phase 3 OASIS-HAE study for their drug donidalorsen, which targets hereditary angioedema (HAE). The press release detailing these findings was made public on January 22, 2024.
For further insights into IONS stock, check out TipRanks’ Stock Analysis page.
